<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="apt15779-tbl-0002" xml:lang="en" content-type="Table" orientation="portrait" position="float">
 <label>Table 2</label>
 <caption>
  <p>IBD medications and infection risk</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <thead valign="top">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="top" rowspan="1" colspan="1"> </th>
    <th align="left" valign="top" rowspan="1" colspan="1">Risk of respiratory tract infections</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Risk of serious infections</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" colspan="3" rowspan="1">Steroids</td>
   </tr>
   <tr>
    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prednisolone</td>
    <td align="left" rowspan="1" colspan="1">
     <p>URTI for influenza compared to placebo 
      <list list-type="bullet" id="apt15779-list-0008">
       <list-item>
        <p>OR 1.22 (95% CI, 1.08‐1.38)
         <xref rid="apt15779-bib-0062" ref-type="ref">
          <sup>62</sup>
         </xref>
        </p>
       </list-item>
      </list>
     </p>
     <p>LRTI compared to placebo 
      <list list-type="bullet" id="apt15779-list-0009">
       <list-item>
        <p>OR 3.62 (95% CI 3.30‐3.98)
         <xref rid="apt15779-bib-0062" ref-type="ref">
          <sup>62</sup>
         </xref>
        </p>
       </list-item>
      </list>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">OR 1.92 (95% CI 0.36‐10.21) compared to placebo
     <xref rid="apt15779-bib-0063" ref-type="ref">
      <sup>63</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Budesonide</td>
    <td align="left" rowspan="1" colspan="1">No increase in adverse events compared with placebo
     <xref rid="apt15779-bib-0118" ref-type="ref">
      <sup>118</sup>
     </xref>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>RR 0.97 (95% CI 0.76‐1.13) compared to placebo
      <xref rid="apt15779-bib-0118" ref-type="ref">
       <sup>118</sup>
      </xref>
     </p>
     <p>OR 0.73 (95% CI 0.36‐1.50) Budesonide MMX compared to placebo
      <xref rid="apt15779-bib-0069" ref-type="ref">
       <sup>69</sup>
      </xref>
     </p>
     <p>OR 0.94 (95% CI 0.56‐1.59) Budesonide compared to placebo
      <xref rid="apt15779-bib-0069" ref-type="ref">
       <sup>69</sup>
      </xref>
     </p>
    </td>
   </tr>
   <tr>
    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Beclomethasone</td>
    <td align="left" rowspan="1" colspan="1">No increase in adverse events compared with placebo
     <xref rid="apt15779-bib-0119" ref-type="ref">
      <sup>119</sup>
     </xref>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>OR 0.30 (95% CI 0.01‐8.29) compared to placebo
      <xref rid="apt15779-bib-0069" ref-type="ref">
       <sup>69</sup>
      </xref>
     </p>
     <p>OR 3.32 (95% CI 0.13‐84.9) compared to prednisolone 
      <xref rid="apt15779-bib-0069" ref-type="ref">
       <sup>69</sup>
      </xref>
     </p>
    </td>
   </tr>
   <tr>
    <td align="left" colspan="3" rowspan="1">Immunomodulators</td>
   </tr>
   <tr>
    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Thiopurines</td>
    <td align="left" rowspan="1" colspan="1">2.1 per patient‐years
     <xref rid="apt15779-bib-0070" ref-type="ref">
      <sup>70</sup>
     </xref>
    </td>
    <td align="left" rowspan="1" colspan="1">OR 0.143 (95% CI 0.43‐4.76) compared to placebo
     <xref rid="apt15779-bib-0070" ref-type="ref">
      <sup>70</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Methotrexate</td>
    <td align="left" rowspan="1" colspan="1">OR 1.02 (95% 0.88‐1.19)
     <xref rid="apt15779-bib-0073" ref-type="ref">
      <sup>73</sup>
     </xref> compared with placebo
    </td>
    <td align="left" rowspan="1" colspan="1">OR 0.52 (95% CI 0.04‐6.34) compared to placebo
     <xref rid="apt15779-bib-0073" ref-type="ref">
      <sup>73</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" colspan="3" rowspan="1">Biologic therapy</td>
   </tr>
   <tr>
    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Anti‐TNF</td>
    <td align="left" rowspan="1" colspan="1">
     <p>URTI 
      <list list-type="bullet" id="apt15779-list-0010">
       <list-item>
        <p>Infliximab: 25% vs 9.8% placebo</p>
       </list-item>
       <list-item>
        <p>Adalimumab: 16.7% vs 14.5% placebo
         <xref rid="apt15779-bib-0076" ref-type="ref">
          <sup>76</sup>
         </xref>
        </p>
       </list-item>
      </list>
     </p>
     <p>LRTI compared to placebo 
      <list list-type="bullet" id="apt15779-list-0011">
       <list-item>
        <p>OR 1.28 (95% CI: 1.08‐1.52)
         <xref rid="apt15779-bib-0062" ref-type="ref">
          <sup>62</sup>
         </xref>
        </p>
       </list-item>
      </list>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">OR 1.43 (95% CI: 1.11‐1.84; 
     <italic>P =</italic> 0.006) compared to placebo
     <xref rid="apt15779-bib-0075" ref-type="ref">
      <sup>75</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ustekinumab</td>
    <td align="left" rowspan="1" colspan="1">
     <p>URTI 
      <list list-type="bullet" id="apt15779-list-0012">
       <list-item>
        <p>10.7% in ustekinumab 12‐weekly and 12.9% ustekinumab 8‐weekly vs 7.5% placebo
         <xref rid="apt15779-bib-0082" ref-type="ref">
          <sup>82</sup>
         </xref>
        </p>
       </list-item>
      </list>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">4.21 (95% CI 3.25‐5.36) in ustekinumab group vs 3.97 (95% CI 2.05‐6.97) in placebo per 100 patient‐years of follow‐up
     <xref rid="apt15779-bib-0082" ref-type="ref">
      <sup>82</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Vedolizumab</td>
    <td align="left" rowspan="1" colspan="1">
     <p>URTI compared to placebo 
      <list list-type="bullet" id="apt15779-list-0013">
       <list-item>
        <p>HR 1.23, log‐rank 
         <italic>P =</italic> .173
         <xref rid="apt15779-bib-0120" ref-type="ref">
          <sup>120</sup>
         </xref>
        </p>
       </list-item>
      </list>
     </p>
     <p>LRTI compared to placebo 
      <list list-type="bullet" id="apt15779-list-0014">
       <list-item>
        <p>HR 0.95, log‐rank 
         <italic>P =</italic> 0.851
         <xref rid="apt15779-bib-0120" ref-type="ref">
          <sup>120</sup>
         </xref>
        </p>
       </list-item>
      </list>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">4.3/100 patient‐years (95% CI 3.7‐4.9) vs 3.8/100 patient‐years (95% CI 1.2‐6.4) for placebo 
     <xref rid="apt15779-bib-0086" ref-type="ref">
      <sup>86</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" colspan="3" rowspan="1">Small molecule therapy</td>
   </tr>
   <tr>
    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Tofacitinib 5 mg</td>
    <td align="left" rowspan="1" colspan="1">
     <p>URTI 
      <list list-type="bullet" id="apt15779-list-0015">
       <list-item>
        <p>4.5% sv 3.3% with placebo in RA patients
         <xref rid="apt15779-bib-0121" ref-type="ref">
          <sup>121</sup>
         </xref>
        </p>
       </list-item>
      </list>
     </p>
     <p>Nasopharyngitis 10% vs 2.8% placebo
      <xref rid="apt15779-bib-0122" ref-type="ref">
       <sup>122</sup>
      </xref>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">2.3 (95% CI: 1.8 to 2.8) /100 patient‐years (in RA)
     <xref rid="apt15779-bib-0123" ref-type="ref">
      <sup>123</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Tofacitinib 10 mg</td>
    <td align="left" rowspan="1" colspan="1">
     <p>URTI 
      <list list-type="bullet" id="apt15779-list-0016">
       <list-item>
        <p>6% vs 4% with placebo in UC patients
         <xref rid="apt15779-bib-0122" ref-type="ref">
          <sup>122</sup>
         </xref>
        </p>
       </list-item>
      </list>
     </p>
     <p>Nasopharyngitis 14% vs 2.8% placebo
      <xref rid="apt15779-bib-0122" ref-type="ref">
       <sup>122</sup>
      </xref>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">2.7 (95% CI: 2.3 to 3.1)/100 patient‐years (in RA)
     <xref rid="apt15779-bib-0123" ref-type="ref">
      <sup>123</sup>
     </xref>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot id="apt15779-ntgp-0002">
  <fn id="apt15779-note-0003">
   <p>Abbreviations: HR, hazard ratio; LRTI, lower respiratory tract infection; OR, odds ratio; RA, rheumatoid arthritis; CI, confidence interval; RR, relative risk; URTI, upper respiratory tract infection.</p>
  </fn>
 </table-wrap-foot>
 <permissions>
  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
  <license>
   <license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p>
  </license>
 </permissions>
</table-wrap>
